E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
non -infectious Uveitis of the Posterior Segment of the Eye |
|
E.1.1.1 | Medical condition in easily understood language |
active, non -infectious Uveitis |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Ocular Physiological Phenomena [G14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036370 |
E.1.2 | Term | Posterior uveitis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA development program. |
|
E.2.2 | Secondary objectives of the trial |
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA development program. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
At Day 1, a subject from the SAKURA program must meet all of the following inclusion criteria:
1. Have a subject number from participation in the SAKURA program
2. Exited the SAKURA program under Amendment 05
3. Have received at least two injections of DE-109 in the first five months of the SAKURA program
4. Received clinical benefit from treatment with DE-109 as determined by the Investigator
5. Female participants of childbearing potential must not be pregnant or breast-feeding, have a negative pregnancy test at Day 1 and must be willing to undergo pregnancy tests throughout the study
6. Both female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, must abstain from
intercourse or must agree to practice acceptable methods of contraception throughout the course of the study
7. Ability to give informed consent and attend all study visits |
|
E.4 | Principal exclusion criteria |
A subject from the SAKURA program with any of the following conditions is not eligible to participate in the study:
Ocular:
1. Active infectious uveitis. However, if the uveitis is the consequence of a previous infectious disease, such as tuberculosis, the previous infectious disease must be confirmed as no longer
active.
2. Any implantable corticosteroid-eluting device (e.g. Ozurdex, I-vation, Iluvien, fluocinolone acetonide [FA] intravitreal implant) in the study eye:
a. If the Investigator confirms the device has no demonstrable efficacy as indicated in the package insert, the subject will be eligible
b. If a Medidur implant, Iluvien or Retisert has been implanted no less than 3 years and 90 days prior to Day 1, the subject will be eligible
c. If a Ozurdex implant has been implanted no less than 180 days prior to Day 1, the subject will be eligible
3. Clinically suspected or confirmed central nervous system or ocular lymphoma
4. Progressive glaucoma which is unresponsive to treatment.
5. Intraocular pressure of > 21 mmHg while on medical therapy, or chronic hypotony (< 6 mmHg)
6. Any significant ocular disease that could compromise vision in the study eye. These include, but are not limited to:
a. Diabetic retinopathy: proliferative diabetic retinopathy (PDR) or non-proliferative diabetic retinopathy (NPDR) that compromises vision. Subjects with NPDR or PDR that does not compromise vision are not excluded from the study;
b. Wet age-related macular degeneration;
c. Myopic degeneration with active subfoveal choroidal neovascularization
7. Any of the following treatments to the study eye:
a. Intravitreal injections in the past 14 days
b. Intravitreal injections of DE-109 in the past 60 days
8. Ocular surgery within the past 30 days
9. Ocular or periocular infection in either eye
10. History of or active herpetic infection in the study eye or adnexa
11. Presence of known active, inactive toxoplasmosis or toxoplasmosis scar in either eye
12. Presence of any form of ocular malignancy in the either eye including choroidal melanoma
13. History of vitrectomy in the study eye
Non-Ocular:
14. Allergy or hypersensitivity to study drug product or other study related procedures/medications
15. Participation in other investigational drug (SAKURA is an exception) or device clinical trials within 30 days prior to Day 1, or planning to participate in other investigational drug or device
clinical trials for the entire duration of the study. This includes both ocular and non-ocular clinical trials.
16. Any recent systemic infection within 30 days of Day 1
17. Known to be immunocompromised
18. History of cytomegalovirus infection or clinical evidence of active cytomegalovirus infection at Day 1
19. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease condition that contraindicates the use of an investigational drug, might affect the interpretation of the results of the study, or renders the subject at high risk for treatment complications
20. Malignancy in remission for less than 5 years prior to study participation (except basal cell or squamous cell skin cancer, or treated melanoma of the skin less than 24 months since last
treatment)
21. Females who are pregnant or lactating and females of child-bearing potential who are not using adequate contraceptive precautions (i.e., intrauterine device, oral contraceptives, barrier
method, or other contraception deemed adequate by the Investigator)
22. Use of medically prescribed marijuana or other illegal medication
23. Active systemic sarcoidosis within the last 30 months (i.e. subjects with uveitis secondary to sarcoidosis will be eligible as long as systemic sarcoidosis is not active and systemic
immunosuppressive therapy has not been given in the last 30 months)
24. Therapeutic radiation to the head or neck within 90 days prior to Day 1 and throughout the study.
In addition, the Investigator or Santen Medical Monitor may declare a subject ineligible for any sound reason. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Collection of long term safety data on DE-109 (440 μg) dose
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
12 months or commercial availability of DE-109, whichever comes first. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 13 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
France |
Germany |
India |
Italy |
Poland |
Turkey |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
All subjects will exit the study at Month 12, unless terminated early
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 12 |
E.8.9.2 | In all countries concerned by the trial days | 0 |